See more : Mitsubishi Shokuhin Co., Ltd. (7451.T) Income Statement Analysis – Financial Results
Complete financial analysis of Sera Prognostics, Inc. (SERA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sera Prognostics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Baillie Gifford US Growth Trust PLC (USA.L) Income Statement Analysis – Financial Results
- Telefónica, S.A. (TEFOF) Income Statement Analysis – Financial Results
- Storytel AB (publ) (STRYF) Income Statement Analysis – Financial Results
- Corporate Universe, Inc. (COUV) Income Statement Analysis – Financial Results
- E’Prime Aerospace Corporation (EPEO) Income Statement Analysis – Financial Results
Sera Prognostics, Inc. (SERA)
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 306.00K | 268.00K | 82.00K | 25.00K | 36.00K |
| Cost of Revenue | 210.00K | 193.00K | 37.00K | 11.00K | 18.00K |
| Gross Profit | 96.00K | 75.00K | 45.00K | 14.00K | 18.00K |
| Gross Profit Ratio | 31.37% | 27.99% | 54.88% | 56.00% | 50.00% |
| Research & Development | 15.23M | 14.24M | 11.02M | 7.78M | 9.35M |
| General & Administrative | 16.34M | 16.78M | 14.09M | 6.56M | 4.28M |
| Selling & Marketing | 8.35M | 14.70M | 10.33M | 3.65M | 2.96M |
| SG&A | 24.69M | 31.48M | 24.42M | 10.20M | 7.24M |
| Other Expenses | 0.00 | 1.53M | 1.13M | -80.00K | -17.00K |
| Operating Expenses | 39.92M | 45.73M | 35.44M | 17.99M | 16.58M |
| Cost & Expenses | 40.13M | 45.92M | 35.48M | 18.00M | 16.60M |
| Interest Income | 1.64M | 456.00K | 145.00K | 42.00K | 64.00K |
| Interest Expense | 55.00K | 61.00K | 746.00K | 1.84M | 1.97M |
| Depreciation & Amortization | 900.00K | 1.22M | 659.00K | 895.00K | 946.00K |
| EBITDA | -35.29M | -42.91M | -33.60M | -17.11M | -13.60M |
| EBITDA Ratio | -11,531.70% | -16,464.55% | -41,784.15% | -68,456.00% | -37,786.11% |
| Operating Income | -39.82M | -45.65M | -35.40M | -17.97M | -16.56M |
| Operating Income Ratio | -13,013.40% | -17,034.33% | -43,164.63% | -71,884.00% | -45,997.22% |
| Total Other Income/Expenses | 3.58M | 1.47M | 386.00K | -1.88M | 55.00K |
| Income Before Tax | -36.24M | -44.19M | -35.01M | -19.85M | -16.52M |
| Income Before Tax Ratio | -11,843.79% | -16,487.31% | -42,693.90% | -79,392.00% | -45,891.67% |
| Income Tax Expense | 0.00 | 61.00K | 1.22M | 1.76M | 3.92M |
| Net Income | -36.24M | -44.25M | -36.23M | -21.61M | -20.44M |
| Net Income Ratio | -11,843.79% | -16,510.07% | -44,180.49% | -86,428.00% | -56,775.00% |
| EPS | -1.16 | -1.43 | -1.18 | -0.70 | -0.67 |
| EPS Diluted | -1.16 | -1.43 | -1.18 | -0.70 | -0.67 |
| Weighted Avg Shares Out | 31.20M | 30.94M | 30.77M | 30.70M | 30.70M |
| Weighted Avg Shares Out (Dil) | 31.20M | 30.94M | 30.77M | 30.70M | 30.70M |
SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES
Sera Prognostics Appoints Dr. Paul Kearney as Chief Data Officer
Sera Prognostics to be Added to Russell 2000 Index
Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
Bullish On 'New Tech' - George Ball Joins Alpha Trader (Podcast)
Sera Prognostics Reports Second Quarter 2021 Financial Results
Sera Prognostics Announces Pricing of Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports